AN2 Therapeutics (ANTX) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for May 22, 2025, with voting on director elections and auditor ratification.

• Proxy materials and annual report for 2024 are available online, with voting accessible by internet, phone, or mail.

• Record date for voting is March 24, 2025, with 30,098,720 shares outstanding.

• Board recommends voting FOR all director nominees and auditor ratification.

Voting matters and shareholder proposals

• Election of three Class III directors (Eric Easom, Stephanie Wong, Joseph Zakrzewski) for terms expiring in 2028.

• Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2025.

• Shareholders may submit proposals for the 2026 meeting by December 11, 2025, or nominate directors per bylaw procedures.

Board of directors and corporate governance

• Board consists of nine members divided into three staggered classes.

• Majority of directors are independent; CEO is not independent.

• Board committees: audit, compensation, nominating and corporate governance, each with defined charters and independent members.

• Lead independent director role established; all directors attended 2024 annual meeting.

• Board diversity and director qualifications emphasized in nomination process.